The two GLP-1 agonists driving the weight management market in 2026. Pick one for the full clinical and pricing picture.
Once-weekly injectable GLP-1 agonist. Approved as Ozempic (T2D), Wegovy (weight management), and Rybelsus (oral T2D). Compounded versions are dispensed by 503A/B pharmacies under prescriber order.
Once-weekly dual-incretin agonist. Approved as Mounjaro (T2D) and Zepbound (weight management). Compounded tirzepatide is similarly dispensed by 503A/B pharmacies.
Five minutes. Free. No pressure.